{"disease":{"id":"glabellar-lines","name":"Glabellar lines","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"botulinum-toxin","indication_name":"Glabellar Lines","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Botulinum Toxin","company_name":"University Health Network, Toronto","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"incobotulinumtoxina","indication_name":"Moderate to severe glabellar lines","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."},{"drug_id":"botulinum-toxin-type-a","indication_name":"Rhytidectomy of glabellar frown lines","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuceiva","generic_name":"BOTULINUM TOXIN TYPE A","company_name":"GlaxoSmithKline K.K.","drug_phase":"marketed","molecular_target":"Synaptosomal-associated protein 25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuceiva works by blocking the release of acetylcholine, a neurotransmitter that transmits signals from nerve cells to muscles, thereby reducing muscle spasms and contractions."},{"drug_id":"incobotulinumtoxina","indication_name":"Glabellar lines","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeomin","generic_name":"INCOBOTULINUMTOXINA","company_name":"Merz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Xeomin works by blocking the release of a chemical messenger called acetylcholine, which signals muscles to contract."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03004248","title":"Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2691,"lead_sponsor_name":"Revance Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07435428","title":"A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT05248893","title":"A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":986,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04157686","title":"MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":957,"lead_sponsor_name":"Medy-Tox","has_results":true},{"nct_id":"NCT01189760","title":"Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":917,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04225260","title":"Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":902,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT00512135","title":"Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":801,"lead_sponsor_name":"Merz Pharmaceuticals GmbH","has_results":true},{"nct_id":"NCT02677298","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":784,"lead_sponsor_name":"Croma-Pharma GmbH","has_results":true},{"nct_id":"NCT05248867","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":638,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05463965","title":"A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":605,"lead_sponsor_name":"Galderma R&D","has_results":false},{"nct_id":"NCT06585696","title":"A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":554,"lead_sponsor_name":"Cutia Therapeutics（Wuxi）Co.,Ltd","has_results":false},{"nct_id":"NCT06499688","title":"A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":529,"lead_sponsor_name":"Chongqing Claruvis Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03216408","title":"Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":504,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT05380154","title":"Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Hugel","has_results":false},{"nct_id":"NCT06583486","title":"A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":488,"lead_sponsor_name":"Chongqing Claruvis Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06246552","title":"Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":480,"lead_sponsor_name":"Jetema USA Inc.","has_results":false},{"nct_id":"NCT06354127","title":"DWP450 for Treating Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":473,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT03732833","title":"MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":425,"lead_sponsor_name":"Medy-Tox","has_results":true},{"nct_id":"NCT03721016","title":"MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":415,"lead_sponsor_name":"Medy-Tox","has_results":true},{"nct_id":"NCT04247074","title":"Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":413,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT03985982","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":410,"lead_sponsor_name":"Croma-Pharma GmbH","has_results":true},{"nct_id":"NCT03736928","title":"Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":401,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT04622254","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":368,"lead_sponsor_name":"Merz North America, Inc.","has_results":true},{"nct_id":"NCT04594213","title":"Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":362,"lead_sponsor_name":"Merz North America, Inc.","has_results":true},{"nct_id":"NCT05100199","title":"A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":328,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT07013279","title":"Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":324,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT05059587","title":"Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"Medytox Korea","has_results":false},{"nct_id":"NCT06205797","title":"To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":312,"lead_sponsor_name":"Huons Biopharma","has_results":false},{"nct_id":"NCT05248880","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":309,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03014635","title":"Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":306,"lead_sponsor_name":"Revance Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03014622","title":"Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":303,"lead_sponsor_name":"Revance Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03960957","title":"Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":301,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT07427797","title":"A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT05804656","title":"Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"CKD Bio Corporation","has_results":false},{"nct_id":"NCT04249583","title":"Treatment of Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT05623410","title":"Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"ATGC Co., Ltd.","has_results":false},{"nct_id":"NCT03289169","title":"Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT04830345","title":"Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":290,"lead_sponsor_name":"EuBiologics Co.,Ltd","has_results":false},{"nct_id":"NCT05531968","title":"Treatment of Moderate to Severe Glabellar Lines (BMI2006)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":278,"lead_sponsor_name":"BMI Korea","has_results":false},{"nct_id":"NCT05364580","title":"The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"Protox Inc.","has_results":false},{"nct_id":"NCT03440671","title":"The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":260,"lead_sponsor_name":"Huons Co., Ltd.","has_results":false},{"nct_id":"NCT00408785","title":"A Study Of BOTOX For The Treatment Of Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT05321979","title":"Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":253,"lead_sponsor_name":"Medytox Korea","has_results":false},{"nct_id":"NCT02677805","title":"Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Croma-Pharma GmbH","has_results":true},{"nct_id":"NCT05089357","title":"Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT03806933","title":"Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":241,"lead_sponsor_name":"Merz Aesthetics GmbH","has_results":true},{"nct_id":"NCT03795922","title":"MT10109L in the Treatment of Glabellar Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":234,"lead_sponsor_name":"Medy-Tox","has_results":true},{"nct_id":"NCT01608672","title":"Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®","phase":"","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04143815","title":"Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT04281745","title":"Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Medy-Tox","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}